Optos reports loss

Article

According to The Financial Times, the retinal imaging company, Optos plc has reported a $4.86 million loss and reduced its headcount by 20%.

According to The Financial Times, the retinal imaging company, Optos plc has reported a $4.86 million loss and reduced its headcount by 20%.

In April last year it launched the P200C which was intended for use in advanced clinical optometry and ophthalmology. Capturing images in the mid to the far periphery of the retina it was potentially able to reach the ora serrata. It planned to market the device on a pay-per-patient basis in the UK, Germany, US and Canada.

The business took an exceptional charge of $4.9 million to cover the costs of refocusing on its core retinal imaging business. CEO, Rod Davis, who was appointed last is reported as saying: "I believe the steps we are taking and the renewed focus on our core optometry business will drive improved business performance in the medium term."

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.